{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:49:05Z","timestamp":1787845745490,"version":"build-2784847793"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory syndrome. Patients with inflammatory bowel diseases (IBD) appear to be at increased risk of developing HLH, potentially due to immunosuppressive therapies. However, the epidemiology, clinical characteristics, management strategies, and outcomes of HLH in this population remain poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review of the literature using PubMed, Web of Science, and Embase. A total of 97 secondary HLH (sHLH) cases and 18 HLH cases with genetic mutations were identified in IBD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among IBD patients, sHLH predominantly affected males with Crohn\u2019s disease, with a median age of 33.5 years and a median disease duration of 4 years. Most patients were on thiopurines for IBD management and were in clinical remission at sHLH onset. The most common triggers were infections (particularly CMV and EBV), followed by lymphoma. The overall survival rate for sHLH was 62.5%. Most patients successfully resumed IBD maintenance therapy within 5 months after the sHLH episode, with minimal complications and rare recurrence of IBD or HLH. Older age, lymphoma-induced HLH, and lack of biologic or thiopurine therapy were potential factors associated with mortality. Compared to sHLH, primary HLH patients were younger, more frequently male, predominantly had Crohn\u2019s disease, were less likely to be in remission despite biologic therapy, and had better outcomes with hematopoietic stem cell transplantation (HSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study provides a comprehensive characterization of HLH in IBD patients, offering valuable insights to guide future research aimed at improving clinical outcomes in this unique population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>osf.io identifier, <jats:ext-link>10.17605\/OSF.IO\/5GY3E<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1575297","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:28:09Z","timestamp":1755235689000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hemophagocytic lymphohistiocytosis in patients with inflammatory bowel diseases: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Tingwei","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14147","article-title":"Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: Differences and similarities","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.10.001","article-title":"Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders","volume":"26","author":"Brisse","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21735","article-title":"New pathogenic paradigms in inflammatory bowel disease","volume":"18","author":"Di Sabatino","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.021","article-title":"A systematic review of monogenic inflammatory bowel disease","volume":"20","author":"Nambu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24331","article-title":"Anti-TNF\u03b1 therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation","volume":"88","author":"Lapsia","year":"2016","journal-title":"J Med Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281f31c","article-title":"Epstein-barr virus in inflammatory bowel disease-correlation with different therapeutic regimens","volume":"19","author":"Magro","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2015.01.015","article-title":"XIAP deficiency syndrome in humans","volume":"39","author":"Latour","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005361","article-title":"Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults","volume":"50","author":"Hines","year":"2022","journal-title":"Crit Care Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20220310-00488","article-title":"\u4e2d\u56fd\u566c\u8840\u7ec6\u80de\u7efc\u5408\u5f81\u8bca\u65ad\u4e0e\u6cbb\u7597\u6307\u5357 (2022 \u5e74\u7248)","volume":"102","year":"2022","journal-title":"Natl Med J China"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-911x(199705)28:5<342::aid-mpo3>3.0.co;2-h","article-title":"HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society","volume":"28","author":"Henter","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12386","article-title":"Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens","volume":"162","author":"Chellapandian","year":"2013","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/coc.0000000000001119","article-title":"Rituximab as a therapeutic strategy in hemophagocytic lymphohistiocytosis: efficacy, outcomes, and survival\u2014Insights from a systematic review","volume":"47","author":"Qureshi","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14029","article-title":"Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: A systematic review","volume":"111","author":"Charlesworth","year":"2023","journal-title":"Eur J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06252-z","article-title":"Hemophagocytic lymphohistiocytosis occurring in inflammatory bowel disease: systematic review","volume":"66","author":"Coburn","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000506514","article-title":"Hemophagocytic lymphohistiocytosis and inflammatory bowel disease: case report and systematic review","volume":"5","author":"Brambilla","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05223-4","article-title":"Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis","volume":"102","author":"Mahmoud","year":"2023","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12305","article-title":"Systematic review: Macrophage activation syndrome in inflammatory bowel disease","volume":"37","author":"Fries","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14933","article-title":"Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"48","author":"de Francisco","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15104","article-title":"Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"49","author":"Ahmed","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/art.42985","article-title":"Emapalumab treatment in patients with rheumatologic disease-associated hemophagocytic lymphohistiocytosis in the United States: A retrospective medical chart review study","volume":"77","author":"Chandrakasan","year":"2024","journal-title":"Arthritis Rheumatol (Hoboken N.J.)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039880","article-title":"Emapalumab as a therapeutic intervention for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A case series","volume":"103","author":"Wang","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012217","article-title":"Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab","volume":"8","author":"Chandrakasan","year":"2024","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1097\/CCE.0000000000001046","article-title":"Ruxolitinib, IV immunoglobulin, and high-dose glucocorticoids for critically ill adults with secondary hemophagocytic lymphohistiocytosis: A single-center observational pilot study","volume":"6","author":"Scholz","year":"2024","journal-title":"Crit Care Explor"},{"key":"B29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bjh.19803","article-title":"Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis","volume":"206","author":"Fang","year":"2024","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.037","article-title":"Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency","volume":"150","author":"Yang","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1575297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:28:10Z","timestamp":1755235690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1575297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1575297"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1575297","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1575297"}}